Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ovid Therapeutics's price to sales ratio was 324.5× on Nov 11, 2026, against 19.2× a year earlier. Over the last 5 years it ranged from 0.9× to 457.0×, with a median of 64.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 324.5× | +306.9 |
| 2025 | Dec 31, 2025 | 17.5× | −87.4 |
| 2024 | Dec 31, 2024 | 104.9× | −63.0 |
| 2023 | Apr 28, 2023 | 167.9× | +77.9 |
| 2022 | Dec 30, 2022 | 90.0× | +89.0 |
| 2021 | Dec 31, 2021 | 1.0× | – |
See a number that looks wrong?